<div id="readability-page-1"><div><p>ADMA Biologics (ADMA) stock has been in focus after short seller Culper Research alleged channel stuffing related to ASCENIV, prompting multiple securities law firms to launch investigations and potential class action lawsuits.</p> <p>See our latest analysis for ADMA Biologics.</p> <p>At a share price of $8.41, ADMA’s recent trading reflects sharp swings, with a 1-day share price gain of 6.73% sitting against a 7-day decline of 17.95% and a 90-day fall of 48.34%. The 5-year total shareholder return remains very large, suggesting long term holders have still seen meaningful gains despite current pressure from legal headlines, competitive IVIG pricing, and trimmed guidance.</p> <p>If this mix of legal risk and long term gains has you rethinking your exposure to healthcare, it could be a useful moment to scan for other potential opportunities in 33 healthcare AI stocks</p> <p>With earnings per share at $0.19, legal questions hanging over ASCENIV and the stock trading well below some analyst targets, investors now face a key question: is there a buying opportunity here, or is future growth already priced in?</p> <h2>Most Popular Narrative: 59.8% Undervalued</h2> <p>According to the most followed narrative, ADMA Biologics' fair value of $20.93 sits well above the last close at $8.41, pointing to a large valuation gap that some investors are watching closely.</p> <blockquote> <p><em>Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF, 134 MUSD, revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029, growth of 21%/year), currently undervalued.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>This narrative leans heavily on rising revenue, wider margins and a future earnings multiple that assumes the business matures into a much larger, more profitable plasma specialist. It highlights the importance of the specific growth and profitability assumptions underlying the $20.93 fair value and how sensitive the estimate may be to relatively small changes in those inputs.</p> <p><strong>Result: Fair Value of $20.93 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on management delivering on growth and margin assumptions while legal investigations into ASCENIV, and any impact on demand or pricing, remain unresolved catalysts.</p> <p>Find out about the key risks to this ADMA Biologics narrative.</p> <h2>Next Steps</h2> <p>If the mix of opportunity and concern in this story leaves you undecided, quickly review the key data and weigh it against your own risk tolerance, including the balance of 3 key rewards and 1 important warning sign.</p> <h2>Looking for more investment ideas?</h2> <p>If ADMA’s situation feels finely balanced, do not stop here. Keep building a watchlist of fresh ideas that fit your style before the next move passes you by.</p> <ul> <li>Target potential mispricings by scanning a focused group of 45 high quality undervalued stocks that combine compelling fundamentals with room for the market to reassess expectations.</li> <li>Prioritise resilience by reviewing solid balance sheet and fundamentals stocks screener (46 results) that may better withstand business shocks and funding pressures over the long haul.</li> <li>Get ahead of the crowd by filtering through a screener containing 22 high quality undiscovered gems that the broader market might not be paying close attention to yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

ADMA

SBIO

IBBQ

LABU

<p>ADMA Biologics (ADMA) faces scrutiny after short seller allegations of channel stuffing related to ASCENIV, leading to investigations and potential lawsuits. The stock, currently priced at $8.41, has seen significant volatility, with a recent 1-day gain of 6.73% but a 7-day decline of 17.95%. Analysts suggest a fair value of $20.93, indicating it may be undervalued. Future growth hinges on management's ability to meet revenue and margin expectations amidst ongoing legal challenges. Investors are advised to weigh risks and consider other opportunities in the healthcare sector.</p>

Simplywall

Adma Biologics

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations